Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 17, 2024

BUY
$182.66 - $235.53 $719,863 - $928,223
3,941 Added 11.14%
39,316 $7.88 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $719,863 - $928,223
3,941 Added 11.14%
39,316 $7.88 Million
Q4 2022

May 17, 2024

BUY
$185.53 - $241.31 $6.56 Million - $8.54 Million
35,375 New
35,375 $8.41 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $4.9 Million - $8.21 Million
35,375 New
35,375 $7.08 Million
Q2 2018

Aug 14, 2018

SELL
$88.31 - $107.8 $852,191 - $1.04 Million
-9,650 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$115.92 - $148.54 $1.12 Million - $1.43 Million
9,650 New
9,650 $1.15 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Portfolio

Follow Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.